Emergent Product Development Seattle,llc

Cecile Morales

William Brady

Philip Tan

Sandy Alexander Simon

Jeffrey A Ledbetter

Martha Susan Hayden-Ledbetter

Peter Armstrong Thompson

Charles G Cerveny

Christy Anne Nilsson

The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.

CD37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof

The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.

CD37 immunotherapeutics and uses thereof

Growing community of inventors

Seattle, WA, United States of America

Cecile Morales